-2.91%
-11.22%
-16.66%
-4.11%
24.20%
-37.23%
-93.35%
AI Spotlight on ASMB
Company Description
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States.The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection.It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV.
The company has collaboration agreements with BeiGene, Ltd.and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc.to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection.
It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC.The company was formerly known as Ventrus Biosciences, Inc.and changed its name to Assembly Biosciences, Inc.
in June 2014.Assembly Biosciences, Inc.was incorporated in 2005 and is headquartered in South San Francisco, California.
Market Data
| Last Price | 14.01 |
| Change Percentage | -2.91% |
| Open | 14.25 |
| Previous Close | 14.43 |
| Market Cap ( Millions) | 89 |
| Volume | 14118 |
| Year High | 19.93 |
| Year Low | 9.84 |
| M A 50 | 15.52 |
| M A 200 | 15.26 |
Financial Ratios
| FCF Yield | 25.65% |
| Dividend Yield | 0.00% |
| ROE | -121.46% |
| Debt / Equity | 5.55% |
| Net Debt / EBIDTA | 58.39% |
| Price To Book | 3.42 |
| Price Earnings Ratio | -2.18 |
| Price To FCF | 3.9 |
| Price To sales | 3.14 |
| EV / EBITDA | -1.34 |
News
- Dec -26 - Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B
- Sep -16 - Is Assembly Biosciences (ASMB) Stock Outpacing Its Medical Peers This Year?
- Jul -15 - Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop
- Jun -10 - Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366
- May -22 - Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024
- May -08 - Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
- Mar -28 - Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights
- Feb -08 - Assembly Biosciences Announces Effective Date of Reverse Stock Split
- Jan -04 - Assembly Biosciences Provides Anticipated Development Milestones for 2024
- Nov -24 - 5 Penny Stocks With Big Black Friday Stock Market News
- Nov -10 - Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Nov -08 - Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer
- Oct -17 - Why Are Stocks Down Today?
- Oct -17 - Why Is Assembly Biosciences (ASMB) Stock Up 92% Today?
- Oct -11 - Assembly Biosciences to Present New Data at AASLD The Liver Meeting®
- Oct -02 - Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor
- Sep -19 - Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting
- Jul -17 - Assembly Biosciences Presents New Data Highlighting Herpes Simplex Virus Development Candidate ABI-5366 at the 47th Annual International Herpesvirus Workshop
- May -23 - Assembly Biosciences to Present During the 2023 Jefferies Healthcare Conference
- Jan -17 - Carver Biosciences Announces Appointment of Three Members to its Scientific Advisory Board
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Novel Therapeutics
Expected Growth : 9.33 %
What the company do ?
Novel Therapeutics from Assembly Biosciences, Inc. are innovative medicines targeting hepatitis B virus and other serious diseases, leveraging a unique approach to inhibit viral replication.
Why we expect these perspectives ?
Assembly Biosciences' Novel Therapeutics segment growth of 9.33% is driven by increasing adoption of its microbiome-based therapies, expansion into new indications, and strategic partnerships. The company's proprietary platform and strong pipeline of candidates also contribute to growth, as well as growing demand for innovative treatments in the infectious disease and oncology markets.
Assembly Biosciences, Inc. Products
| Product Range | What is it ? |
|---|---|
| HBV Core Inhibitor | A novel class of oral therapeutic agents designed to inhibit the activity of the hepatitis B virus (HBV) core protein, which is essential for the virus's replication. |
| HBV RNA Destabilizer | A new class of oral therapeutic agents designed to destabilize the hepatitis B virus (HBV) RNA, which is essential for the virus's replication. |
| HBV cccDNA Inhibitor | A novel class of oral therapeutic agents designed to inhibit the formation of covalently closed circular DNA (cccDNA), which is the viral reservoir that perpetuates chronic hepatitis B infection. |
| HBV Therapeutic Vaccine | A novel therapeutic vaccine designed to stimulate the immune system to recognize and eliminate hepatitis B virus (HBV)-infected cells. |
Assembly Biosciences, Inc.'s Porter Forces
Threat Of Substitutes
Assembly Biosciences, Inc. has a moderate threat of substitutes due to the availability of alternative treatments for viral diseases and liver diseases.
Bargaining Power Of Customers
Assembly Biosciences, Inc. has a low bargaining power of customers due to the lack of negotiating power of individual customers.
Bargaining Power Of Suppliers
Assembly Biosciences, Inc. has a moderate bargaining power of suppliers due to the availability of multiple suppliers for raw materials and services.
Threat Of New Entrants
Assembly Biosciences, Inc. has a high threat of new entrants due to the attractiveness of the biotechnology industry and the availability of funding for startups.
Intensity Of Rivalry
Assembly Biosciences, Inc. operates in a highly competitive industry with several established players, leading to a high intensity of rivalry.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 5.39% |
| Debt Cost | 3.95% |
| Equity Weight | 94.61% |
| Equity Cost | 6.99% |
| WACC | 6.83% |
| Leverage | 5.70% |
Assembly Biosciences, Inc. : Quality Control
Assembly Biosciences, Inc. passed 6 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| FULC | Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in … |
| CLSD | Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone … |
| XERS | Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for … |
| CRDF | Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer … |
| ATNM | Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Xeris Biopharma
A-Score
1-Year Total Return ->
🥈
Cardiff Oncology
A-Score
1-Year Total Return ->
🥉
Assembly Biosciences
A-Score
1-Year Total Return ->
4
Clearside Biomedical
A-Score
1-Year Total Return ->
5
Fulcrum Therapeutics
A-Score
1-Year Total Return ->
6
